Consumption of gluten with gluten-degrading enzyme by celiac patients: A pilot-study

World Journal of Gastroenterology

Volumn 19, Issue 35, 2013, Pages 5837-5847

  Tack, Greetje J ^a   van de Water, Jolanda M W ^a   Bruins, Maaike J ^b   Kooy Winkelaar, Engelina M C ^c   van Bergen, Jeroen ^c   Bonnet, Petra ^a   Vreugdenhil, Anita C E ^d   Korponay Szabo, Ilma ^e,f   Edens, Luppo ^b   von Blomberg, B Mary E ^a   Schreurs, Marco W J ^a   Mulder, Chris J ^a   Koning, Frits ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b DSM RESOLVE   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF DEBRECEN   (Hungary)

^f TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Adverse events; Aspergillus niger prolyl endoprotease; Celiac disease; Efficacy; Enzyme; Gluten; IgA tTG intestinal deposits; Prolyl endoprotease; Treatment

Indexed keywords

ASPERGILLUS NIGER PROLYL ENDOPROTEASE; ENDOMYSIUM ANTIBODY; GLUTEN; PLACEBO; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY; PROTEINASE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CELIAC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DUODENUM BIOPSY; DUODENUM MUCOSA; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; IMMUNOPHENOTYPING; MALE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE;

ADVERSE EVENTS; ASPERGILLUS NIGER PROLYL ENDOPROTEASE; CELIAC DISEASE; EFFICACY; ENZYME; GLUTEN; IGA-TTG INTESTINAL DEPOSITS; PROLYL ENDOPROTEASE; TREATMENT;

ADULT; AGED; ANTIBODIES; ASPERGILLUS NIGER; ATROPHY; BIOPSY; CELIAC DISEASE; DOUBLE-BLIND METHOD; DUODENUM; ENZYME THERAPY; FEMALE; FUNGAL PROTEINS; GLUTENS; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; NETHERLANDS; PILOT PROJECTS; QUALITY OF LIFE; SERINE ENDOPEPTIDASES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84885642584     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i35.5837     Document Type: Article

References (30)

1. Dubé C, Rostom A, Sy R, Cranney A, Saloojee N, Garritty C, Sampson M, Zhang L, Yazdi F, Mamaladze V, Pan I, Macneil J, Mack D, Patel D, Moher D. The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review. Gastroenterology 2005; 128: S57-S67 [PMID: 15825128 DOI: 10.1053/j.gastro.2005.02.014]
2. Green PH, Cellier C. Celiac disease. N Engl J Med 2007; 357: 1731-1743 [PMID: 17960014 DOI: 10.1056/NEJMra071600]
3. Casellas F, Rodrigo L, Vivancos JL, Riestra S, Pantiga C, Baudet JS, Junquera F, Diví VP, Abadia C, Papo M, Gelabert J, Malagelada JR. Factors that impact health-related quality of life in adults with celiac disease: a multicenter study. World J Gastroenterol 2008; 14: 46-52 [PMID: 18176960 DOI: 10.3748/wjg.14.46]
4. Whitaker JK, West J, Holmes GK, Logan RF. Patient perceptions of the burden of coeliac disease and its treatment in the UK. Aliment Pharmacol Ther 2009; 29: 1131-1136 [PMID: 19245681 DOI: 10.1111/j.1365-2036.2009.03983.x]
5. Wieser H. The precipitating factor in coeliac disease. Baillieres Clin Gastroenterol 1995; 9: 191-207 [PMID: 7549024 DOI: 10.1016/0950-3528(95)90027-6]
6. Shan L, Molberg Ø, Parrot I, Hausch F, Filiz F, Gray GM, Sollid LM, Khosla C. Structural basis for gluten intolerance in celiac sprue. Science 2002; 297: 2275-2279 [PMID: 12351792 DOI: 10.1126/science.1074129]
7. Hausch F, Shan L, Santiago NA, Gray GM, Khosla C. Intestinal digestive resistance of immunodominant gliadin peptides. Am J Physiol Gastrointest Liver Physiol 2002; 283: G996-G1003 [PMID: 12223360]
8. Gass J, Ehren J, Strohmeier G, Isaacs I, Khosla C. Fermentation, purification, formulation, and pharmacological evaluation of a prolyl endopeptidase from Myxococcus xanthus: implications for Celiac Sprue therapy. Biotechnol Bioeng 2005; 92: 674-684 [PMID: 16136593]
9. Shan L, Marti T, Sollid LM, Gray GM, Khosla C. Comparative biochemical analysis of three bacterial prolyl endopeptidases: implications for coeliac sprue. Biochem J 2004; 383: 311-318 [PMID: 15245330]
10. Polgár L. Prolyl endopeptidase catalysis. A physical rather than a chemical step is rate-limiting. Biochem J 1992; 283 (Pt 3): 647-648 [PMID: 1590752 DOI: 10.1111/j.1432-1033.1991. tb15930.x]
11. Stepniak D, Spaenij-Dekking L, Mitea C, Moester M, de Ru A, Baak-Pablo R, van Veelen P, Edens L, Koning F. Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease. Am J Physiol Gastrointest Liver Physiol 2006; 291: G621-G629 [PMID: 16690904 DOI: 10.1152/ajpgi.00034.2006]
12. Mitea C, Havenaar R, Drijfhout JW, Edens L, Dekking L, Koning F. Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease. Gut 2008; 57: 25-32 [PMID: 17494108 DOI: 10.1136/ gut.2006.111609]
13. Edens L, Dekker P, van der Hoeven R, Deen F, de Roos A, Floris R. Extracellular prolyl endoprotease from Aspergillus niger and its use in the debittering of protein hydrolysates. J Agric Food Chem 2005; 53: 7950-7957 [PMID: 16190655]
14. Häuser W, Gold J, Stallmach A, Caspary WF, Stein J. Development and validation of the Celiac Disease Questionnaire (CDQ), a disease-specific health-related quality of life measure for adult patients with celiac disease. J Clin Gastroenterol 2007; 41: 157-166 [PMID: 17245214]
15. Rostami K, Kerckhaert J, Tiemessen R, von Blomberg BM, Meijer JW, Mulder CJ. Sensitivity of antiendomysium and antigliadin antibodies in untreated celiac disease: disappointing in clinical practice. Am J Gastroenterol 1999; 94: 888-894 [PMID: 10201452 DOI: 10.1111/j.1572-0241.1999.983_f.x]
16. Verbeek WH, von Blomberg BM, Coupe VM, Daum S, Mulder CJ, Schreurs MW. Aberrant T-lymphocytes in refractory coeliac disease are not strictly confined to a small intestinal intraepithelial localization. Cytometry B Clin Cytom 2009; 76: 367-374 [PMID: 19444812 DOI: 10.1002/cyto.b.20481]
17. van de Wal Y, Kooy YM, van Veelen PA, Peña SA, Mearin LM, Molberg O, Lundin KE, Sollid LM, Mutis T, Benckhuijsen WE, Drijfhout JW, Koning F. Small intestinal T cells of celiac disease patients recognize a natural pepsin fragment of gliadin. Proc Natl Acad Sci USA 1998; 95: 10050-10054 [PMID: 9707598]
18. Kaukinen K, Peräaho M, Collin P, Partanen J, Woolley N, Kaartinen T, Nuutinen T, Halttunen T, Mäki M, Korponay-Szabo I. Small-bowel mucosal transglutaminase 2-specific IgA deposits in coeliac disease without villous atrophy: a prospective and randomized clinical study. Scand J Gastroenterol 2005; 40: 564-572 [PMID: 16036509 DOI: 10.1080/0036 5520510023422]
19. Lerner A, Kumar V, Iancu TC. Immunological diagnosis of childhood coeliac disease: comparison between antigliadin, antireticulin and antiendomysial antibodies. Clin Exp Immunol 1994; 95: 78-82 [PMID: 8287612 DOI: 10.1111/ j.1365-2249.1994.tb06018.x]
20. Lewis NR, Scott BB. Meta-analysis: deamidated gliadin peptide antibody and tissue transglutaminase antibody compared as screening tests for coeliac disease. Aliment Pharmacol Ther 2010; 31: 73-81 [PMID: 19664074]
21. Korponay-Szabó IR, Halttunen T, Szalai Z, Laurila K, Király R, Kovács JB, Fésüs L, Mäki M. In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies. Gut 2004; 53: 641-648 [PMID: 15082580 DOI: 10.1136/gut.2003.024836]
22. Mohamed BM, Feighery C, Coates C, O'Shea U, Delaney D, O'Briain S, Kelly J, Abuzakouk M. The absence of a mucosal lesion on standard histological examination does not exclude diagnosis of celiac disease. Dig Dis Sci 2008; 53: 52-61 [PMID: 17487584 DOI: 10.1007/s10620-007-9821-5]
23. Koskinen O, Collin P, Korponay-Szabo I, Salmi T, Iltanen S, Haimila K, Partanen J, Mäki M, Kaukinen K. Gluten-dependent small bowel mucosal transglutaminase 2-specific IgA deposits in overt and mild enteropathy coeliac disease. J Pediatr Gastroenterol Nutr 2008; 47: 436-442 [PMID: 18852635 DOI: 10.1097/MPG.0b013e31817b6dec]
24. van Overbeek FM, Uil-Dieterman IG, Mol IW, Köhler-Brands L, Heymans HS, Mulder CJ. The daily gluten intake in relatives of patients with coeliac disease compared with that of the general Dutch population. Eur J Gastroenterol Hepatol 1997; 9: 1097-1099 [PMID: 9431901]
25. Cornell HJ, Macrae FA, Melny J, Pizzey CJ, Cook F, Mason S, Bhathal PS, Stelmasiak T. Enzyme therapy for management of coeliac disease. Scand J Gastroenterol 2005; 40: 1304-1312 [PMID: 16243716 DOI: 10.1080/00365520510023855]
26. Montgomery AM, Goka AK, Kumar PJ, Farthing MJ, Clark ML. Low gluten diet in the treatment of adult coeliac disease: effect on jejunal morphology and serum anti-gluten antibodies. Gut 1988; 29: 1564-1568 [PMID: 3209114 DOI: 10.1136/gut.29.11.1564]
27. Kumar PJ, O'Donoghue DP, Stenson K, Dawson AM. Re-introduction of gluten in adults and children with treated coeliac disease. Gut 1979; 20: 743-749 [PMID: 499912 DOI: 10.1136/gut.20.9.743]
28. Wahab PJ, Crusius JB, Meijer JW, Mulder CJ. Gluten challenge in borderline gluten-sensitive enteropathy. Am J Gastroenterol 2001; 96: 1464-1469 [PMID: 11374684 DOI: 10.1016/S0002-9270(01)02375-9]
29. Lanzini A, Lanzarotto F, Villanacci V, Mora A, Bertolazzi S, Turini D, Carella G, Malagoli A, Ferrante G, Cesana BM, Ricci C. Complete recovery of intestinal mucosa occurs very rarely in adult coeliac patients despite adherence to glutenfree diet. Aliment Pharmacol Ther 2009; 29: 1299-1308 [PMID: 19302264 DOI: 10.1111/j.1365-2036.2009.03992.x]
30. Leffler D, Schuppan D, Pallav K, Najarian R, Goldsmith JD, Hansen J, Kabbani T, Dennis M, Kelly CP. Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Gut 2013; 62: 996-1004 [PMID: 22619366 DOI: 10.1136/gutjnl-2012-302196]